title: Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
authors.affiliation: Department of Endocrine Oncology, University Hospital, Uppsala, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Oberg
authors.forename: P
authors.initials: P
authors.lastname: Hellman
authors.forename: D
authors.initials: D
authors.lastname: Kwekkeboom
authors.forename: S
authors.initials: S
authors.lastname: Jelic
mesh_terms: D001707:Biopsy, Needle; D053379:Chromogranin A / Q000378:metabolism; D003603:Cytotoxins / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004621:Embolization, Therapeutic; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis / Q000628:therapy; D009367:Neoplasm Staging; D018570:Risk Assessment; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016019:Survival Analysis; D013953:Thymus Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D053379:Chromogranin A; D003603:Cytotoxins; D016898:Interferon-alpha; D013004:Somatostatin